No profile data available.
Veracyte, Inc. (VCYT) is a healthcare company in the DNA testing equipment industry, based in South San Francisco, United States, with about 755 full-time employees.
It reported revenue of $517.15 million for fiscal year 2025, up 16.0% from fiscal year 2024, and net income of $66.35 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $150.32 million, up 15.5% from a year before. United States was its largest region in fiscal year 2025, with 96% of revenue. Its market capitalization was $3.64 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally.
Veracyte reported $517.15 million in revenue for fiscal year 2025, up 16.0% from $445.76 million in fiscal year 2024. In Q2 2026 revenue was $150.32 million.
United States: 96% of revenue by region in fiscal year 2025, followed by International (4%).
$3.64 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (DNA testing equipment) include Caris Life Sciences, Inc. (CAI), Grail, Inc. (GRAL), Adaptive Biotechnologies Corporation (ADPT), CareDx, Inc (CDNA).